7,172 Shares in ResMed Inc. $RMD Purchased by Caprock Group LLC

Caprock Group LLC acquired a new stake in ResMed Inc. (NYSE:RMD) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 7,172 shares of the medical equipment provider’s stock, valued at approximately $1,973,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quadcap Wealth Management LLC increased its position in shares of ResMed by 2.5% during the second quarter. Quadcap Wealth Management LLC now owns 1,880 shares of the medical equipment provider’s stock valued at $485,000 after acquiring an additional 45 shares during the last quarter. NBT Bank N A NY grew its stake in ResMed by 22.9% in the 3rd quarter. NBT Bank N A NY now owns 252 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 47 shares during the period. OFI Invest Asset Management increased its position in shares of ResMed by 10.4% during the 3rd quarter. OFI Invest Asset Management now owns 509 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 48 shares during the last quarter. New Wave Wealth Advisors LLC raised its stake in shares of ResMed by 2.8% during the 3rd quarter. New Wave Wealth Advisors LLC now owns 1,899 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 52 shares during the period. Finally, Miracle Mile Advisors LLC boosted its holdings in shares of ResMed by 4.9% in the 3rd quarter. Miracle Mile Advisors LLC now owns 1,150 shares of the medical equipment provider’s stock worth $315,000 after buying an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Analyst Ratings Changes

RMD has been the subject of a number of research analyst reports. UBS Group restated a “buy” rating and set a $345.00 price objective on shares of ResMed in a report on Friday, December 12th. Morgan Stanley set a $305.00 price target on shares of ResMed in a research note on Friday, October 31st. Royal Bank Of Canada upped their price objective on ResMed from $311.00 to $314.00 and gave the company an “outperform” rating in a research note on Friday, January 30th. Wall Street Zen raised ResMed from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Finally, KeyCorp restated an “overweight” rating and issued a $302.00 target price on shares of ResMed in a research note on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $299.27.

ResMed Stock Performance

Shares of RMD opened at $252.47 on Friday. ResMed Inc. has a 52-week low of $199.92 and a 52-week high of $293.81. The stock’s 50-day simple moving average is $252.55 and its 200 day simple moving average is $262.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. The stock has a market capitalization of $36.78 billion, a price-to-earnings ratio of 24.97, a price-to-earnings-growth ratio of 1.63 and a beta of 0.87.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the firm earned $2.43 EPS. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Research analysts forecast that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, February 12th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, February 12th. ResMed’s dividend payout ratio (DPR) is presently 23.74%.

Insider Buying and Selling at ResMed

In other ResMed news, Director Witte Jan De sold 2,055 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total value of $524,025.00. Following the transaction, the director directly owned 4,261 shares in the company, valued at $1,086,555. This represents a 32.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $251.31, for a total value of $502,620.00. Following the completion of the sale, the director directly owned 64,773 shares in the company, valued at approximately $16,278,102.63. The trade was a 3.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 18,137 shares of company stock valued at $4,658,832 in the last three months. Company insiders own 0.65% of the company’s stock.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.